Risperidone, long-acting injectable
Sponsors
Janssen Pharmaceutica N.V., Belgium, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions
Schizoaffective DisorderSchizophrenia
Phase 3
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
CompletedNCT00216580
Start: 2004-02-29End: 2006-12-31Updated: 2013-03-25
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
CompletedNCT00297388
End: 2004-09-30Updated: 2011-05-18